We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Fig. 1 · Structure
Cat. No.
A10938
CAS No.
97240-79-4
Formula
C12H21NO8S
Mol. Weight
339.36

Documents & Downloads

Topiramate

Antiepileptic Agent

Topiramate is a broad-spectrum antiepileptic agent that primarily targets the enhancement of GABAergic activity while acting as a GluR5 receptor antagonist. It exerts its antiepileptic effects through multiple mechanisms, including the inhibition of kainate/AMPA receptors and voltage-sensitive sodium and calcium channels, as well as increasing potassium conductance and inhibiting carbonic anhydrase. This compound is widely utilized in neurological research to investigate seizure mechanisms and develop treatment strategies for epilepsy.

In Stock

Notify me when the price drops

For laboratory research use only. We do not sell to patients.

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vivo Studies

In Ekkwill-strain zebrafish larvae exposed to PTZ at 20 mM, incubation with Topiramate at 200 µM decreased PTZ-induced locomotor activity compared with VHC+PTZ controls. In Scn1a +/− mice, a single intraperitoneal injection of Topiramate at 40 mg/kg had no effect on hyperthermia-induced seizure thresholds compared with matched vehicle controls. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Topiramate and PTZ-Induced Movement in Zebrafish Larvae

Animal study · Zebrafish (Danio rerio) stocks of the Ekkwill strain; larvae of 7 days post-fertilization (dpf) [1]

Ekkwill-strain zebrafish larvae were incubated with Topiramate at 200 µM, with PTZ at 20 mM. Topiramate decreased PTZ-induced locomotor activity compared with VHC+PTZ controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
average larval locomotor activity within 30 minutesReported result Topiramate (200 µM); PTZ at 20 mM: TPR (p<0.001) decreased PTZ-induced movement compared to VHC+PTZ controls within the 30-min integration time.[1]

Conditions shared by the study groups

Route
incubated with AEDs
Treatment course
30-min integration time
Vehicle
DMSO concentration of 1% w/v
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Topiramate 200 µMVHC+PTZ controlsTopiramate (200 µM); PTZ at 20 mM: TPR (p<0.001) decreased PTZ-induced movement compared to VHC+PTZ controls within the 30-min integration time.[1]
Topiramate 200 µM
Model: Zebrafish (Danio rerio) stocks of the Ekkwill strain; larvae of 7 days post-fertilization (dpf)
Methods and source locations

Compound reported in the paper: Topiramate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1, S4); Materials and Methods > Drugs (S6, S8); Materials and Methods > Toxicological Evaluation (S11); Results > Proconvulsant Treatment (S30); Results > Test of AEDs in the Larval Zebrafish PTZ Assay (S38); Figure 3 legend (S58); Table 1 (T1.h1, T1.h2, T1.r11)

average larval locomotor activity within 30 minutes: average larval locomotor activity within 30 minutes; comparator: VHC+PTZ controls — Results > Proconvulsant Treatment (S30); Results > Test of AEDs in the Larval Zebrafish PTZ Assay (S38); Figure 3 legend (S58); Table 1 (T1.r11)

Topiramate 200 µM · Materials and Methods > Toxicological Evaluation (S11); Results > Proconvulsant Treatment (S30); Results > Test of AEDs in the Larval Zebrafish PTZ Assay (S38); Table 1 (T1.h1, T1.h2, T1.r11)

Topiramate and Hyperthermia-Induced Seizure Thresholds in Mice

Animal study · Scn1a +/− mice at age postnatal day 14‐16 (P14‐16) [2]

Scn1a +/− mice received a single intraperitoneal injection of Topiramate at 40 mg/kg. Topiramate had no effect on hyperthermia-induced seizure thresholds compared with matched vehicle controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
hyperthermia‐induced seizure thresholdsReported result 40 mg/kg topiramate; single intraperitoneal (ip) injection: Topiramate had no effect at the administered doses targeting the human therapeutic range.[2]

Conditions shared by the study groups

Route
intraperitoneal (ip) injection
Treatment course
single intraperitoneal (ip) injection
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Topiramate 40 mg/kgMatched vehicle controls40 mg/kg topiramate; single intraperitoneal (ip) injection: Topiramate had no effect at the administered doses targeting the human therapeutic range.[2]
Topiramate 40 mg/kg
Model: Scn1a +/− mice at age postnatal day 14‐16 (P14‐16)
Methods and source locations

Compound reported in the paper: Topiramate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Drugs (S14, S15, S16); Materials and Methods > Hyperthermia‐induced seizures (S41, S50); Results > Evaluation of anticonvulsant drugs against hyperthermia‐induced seizures (S99, S107, S113)

hyperthermia‐induced seizure thresholds: hyperthermia‐induced seizure thresholds; comparator: Matched vehicle controls — Materials and Methods > Drugs (S15, S16); Results > Evaluation of anticonvulsant drugs against hyperthermia‐induced seizures (S107, S113)

Topiramate 40 mg/kg · Materials and Methods > Drugs (S15, S16); Results > Evaluation of anticonvulsant drugs against hyperthermia‐induced seizures (S113)

Specifications

Manufacturer Adooq Bioscience
CAS Number 97240-79-4
Applications Antiepileptic Agent
Formula C12H21NO8S
Molecular Weight 339.36
Synonyms McN 4853; RWJ 17021
SMILES
NS(OC[C@]1(OC(C)(C)O2)[C@@H]2[C@H](OC(C)(C)O3)[C@H]3CO1)(=O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Afrikanova T, Serruys AS, Buenafe OE, et al. Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs. PLoS One (2013). PMID: 23342097 DOI: 10.1371/journal.pone.0054166 Source material
  2. [2] Hawkins NA, Anderson LL, Gertler TS, et al. Screening of conventional anticonvulsants in a genetic mouse model of epilepsy. Ann Clin Transl Neurol (2017). PMID: 28491900 DOI: 10.1002/acn3.413 Source material

Added to your cart

View Cart Checkout
Loading...